Viracta Therapeutics, Inc. Stock Nasdaq
Equities
US92765F1084
Biotechnology & Medical Research
Financials (USD)
Sales 2024 * | - | Sales 2025 * | 2.33M | Capitalization | 33.26M |
---|---|---|---|---|---|
Net income 2024 * | -62M | Net income 2025 * | -86M | EV / Sales 2024 * | - |
Net cash position 2024 * | - | Net cash position 2025 * | - | EV / Sales 2025 * | 14.3 x |
P/E ratio 2024 * |
-0.73
x | P/E ratio 2025 * |
-0.76
x | Employees | 40 |
Yield 2024 * |
-
| Yield 2025 * |
-
| Free-Float | 97.08% |
Latest transcript on Viracta Therapeutics, Inc.
Managers | Title | Age | Since |
---|---|---|---|
Mark Rothera
CEO | Chief Executive Officer | 62 | 22-09-18 |
Melody Burcar
DFI | Director of Finance/CFO | 41 | 22-08-31 |
Chief Tech/Sci/R&D Officer | - | - |
Members of the board | Title | Age | Since |
---|---|---|---|
Ivor Royston
BRD | Director/Board Member | 79 | 07-09-30 |
Thomas Darcy
BRD | Director/Board Member | 74 | 21-01-31 |
Barry Simon
BRD | Director/Board Member | 69 | 21-03-02 |
1st Jan change | Capi. | |
---|---|---|
+2.01% | 42.59B | |
+8.25% | 40.65B | |
+49.22% | 40.57B | |
-11.96% | 26.77B | |
+9.10% | 24.81B | |
-24.25% | 18.17B | |
+27.24% | 12.05B | |
-3.25% | 11.7B | |
+6.92% | 11.1B |